In dogs included in this study, 80% of intestinal carcinomas and a high proportion of rectal carcinomas (42%) were HER2 positive, suggesting that tumours of intestinal origin may potentially benefit from HER2-directed therapy. The gene discussed is ERBB2; the disease is rectal carcinoma.